Search Results - "Schiappa, R."

A refined molecular taxonomy of breast cancer by Guedj, M, Marisa, L, de Reynies, A, Orsetti, B, Schiappa, R, Bibeau, F, MacGrogan, G, Lerebours, F, Finetti, P, Longy, M, Bertheau, P, Bertrand, F, Bonnet, F, Martin, A L, Feugeas, J P, Bièche, I, Lehmann-Che, J, Lidereau, R, Birnbaum, D, Bertucci, F, de Thé, H, Theillet, C

“…The current histoclinical breast cancer classification is simple but imprecise. Several molecular classifications of breast cancers based on expression…”
Get full text

The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca2+ homeostasis by Gueguinou, M, Crottès, D, Chantôme, A, Rapetti-Mauss, R, Potier-Cartereau, M, Clarysse, L, Girault, A, Fourbon, Y, Jézéquel, P, Guérin-Charbonnel, C, Fromont, G, Martin, P, Pellissier, B, Schiappa, R, Chamorey, E, Mignen, O, Uguen, A, Borgese, F, Vandier, C, Soriani, O

“…The remodeling of calcium homeostasis contributes to the cancer hallmarks and the molecular mechanisms involved in calcium channel regulation in tumors remain…”
Get full text

Factors Involved in Delaying Initiation of Adjuvant Chemotherapy After Breast Cancer Surgery by Meyer, C., Bailleux, C., Chamorey, E., Schiappa, R., Delpech, Y., Dejode, M., Fouché, Y., Haudebourg, J., Barranger, E.

“…Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of…”
Get full text

Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: A multicenter retrospective analysis by Baron, D., Pasquier, D., Pace-Loscos, T., Vandendorpe, B., Schiappa, R., Ortholan, C., Hannoun-Levi, J.M.

“…•Systemic therapies are the standard treatment for metastatic castration resistant prostate cancer.•Systemic therapies are associated with numerous side…”
Get full text

Response to “Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients – A closer inspection will improve your vision” by Baron, D., Pasquier, D., Pace-Loscos, T., Vandendorpe, B., Schiappa, R., Ortholan, C., Hannoun-Levi, J.M.

Get full text

Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer by Baron, D., Pasquier, D., Pace-Loscos, T., Vandendorpe, B, Schiappa, R., Ortholan, C., Hannoun-Levi, J.M.

“…PurposeTo evaluate the oncological outcome after stereotactic body radiation therapy (SBRT) for oligometastatic hormone-sensitive prostate cancer (omHSPC)…”
Get full text

Combining Stereotactic Radiotherapy and Conventional Radiotherapy for Peripheral Locally Advanced Lung Cancer by Boutros, J., Martin, N., Otto, J., Marquette, C.-H., Lhomel, B., Naghavi, A.O., Schiappa, R., Bondiau, P.-Y., Doyen, J.

Get full text

18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns by Humbert, O., Cadour, N., Paquet, M., Schiappa, R., Poudenx, M., Chardin, D., Borchiellini, D., Benisvy, D., Ouvrier, M. J., Zwarthoed, C., Schiazza, A., Ilie, M., Ghalloussi, H., Koulibaly, P. M., Darcourt, J., Otto, J.

“…Purpose This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe…”
Get full text

Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study by Saint, Angélique, Viotti, J., Borchiellini, D., Hoch, B., Raimondi, V., Hebert, C., Largillier, R., Evesque, L., Follana, P., Ferrero, J. M., Delaby, C., Schiappa, R., Chamorey, E., Barriere, J.

“…Purpose Anemia is common in oncology and negatively impacts quality of life. However, there is lack of knowledge about iron deficiency (ID) epidemiology. The…”
Get full text

Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35Gy in 5 fractions by Sumodhee, S., Atallah, V., Kinj, R., Doyen, J., L’Homel, B., Gillon, P., Paquis, P., Almairac, F., Hieronimus, S., Schiappa, R., Sadoul, J.-L., Sumodhee, D., Pontikos, N., Richier, Q., Hannoun-Levi, J.-M., Scouarnec, C., Chevalier, N., Bondiau, P.-Y.

“…Evaluate efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) for patients treated for pituitary adenoma (PA) with an alternative HSRT…”
Get full text

BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL) by Gallamini, A., Schiano de Colella, J., Viotti, J., Bijou, F., Rambaldi, A., Perrot, A., Patti, C., Gastaud, L., Sorasio, R., Debaigt, C., Schiappa, R., Chamorey, E., Viviani, S., Thyss, A.

Get full text

Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab by Verriere, B., Gastaud, L., Chamorey, E., Peyrade, F., Deletie, E., Bouredji, K., Quinsat, D., Schiappa, R., Thyss, A., Re, D.

“…Bendamustine (B) associated with rituximab (R) is widely described in literature for the management of patients with chronic lymphoid leukaemia (CLL) and…”
Get full text

Oncological Outcomes and Toxicities of Brachytherapy for Carcinomas of the Penis: A Bi-Centric Study by the SFRO Brachytherapy Group by KA, K., Schiappa, R., Espenel, S., Hannoun-Levi, J.M., Chargari, C.

“…Total glansectomy and brachytherapy represent therapeutic choices for penile cancers. However, to avoid the functional sequelae associated with surgery,…”
Get full text

Prostate Brachytherapy Boost in the Elderly: Results of a Comparative Study by Marotte, D., Gal, J., Schiappa, R., Gautier, M., Boulahssass, R., Chand, M.E., Levi, J.M. Hannoun

Get full text

Single Fraction HDR Brachytherapy for Prostate Cancer: SiFEPI Phase II Trial Results by Pujol, N., Pace-Loscos, T., Schiappa, R., Gautier, M., Chand, M.E., Levi, J.M. Hannoun

Get full text

Second Conservative Treatment for Ipsilateral Breast Cancer Recurrence: First 10-Year Oncological Outcome Report by Levi, J.M. Hannoun, Gal, J., Schiappa, R., Gautier, M., Chand, M.E.

Get full text

Systemic Therapy Postponement after Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer by Baron, D., Pace-Loscos, T., Schiappa, R., Ortholan, C., Pasquier, D., Levi, J.M. Hannoun

Get full text

362P CYBERNEO trial: Update of results at 14 years of follow-up by Ben Dhia, S., Schiappa, R., Gal, J., Ferrero, J-M., Bahadoran, P., Chapellier, C., Bondiau, P-Y.

Get full text

OC-0916 2nd conservative treatment for 2nd breast tumor event: a GEC-ESTRO prognostic factor analysis by Hannoun-Levi, J., Gal, J., Polgar, C., Strnad, V., Loessl, K., Polat, B., Kauer-Domer, D., Schiappa, R., Gutierrez, C.

Get full text

Very APBI in 1 or 2 Days: Late Toxicity and Early Oncological Outcomes of the GEC-ESTRO Cohort by Hannoun-Levi, J.M., Morales, M. Gimeno, Gal, J., Anchuelo, J., Guinot, J.L., Boronat, M. Gaztanaga, Meszaros, N., Polgar, C., Strnad, V., Schiappa, R., Gutierrez, C.

“…To analyze late toxicity after very accelerated partial breast irradiation (VAPBI) for low-risk breast cancer. In this retrospective observational…”
Get full text